drugset

drugset / Trial / NCT02641522

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522 ↗

Phase 0 Completed 10 enrolled Carla Greenbaum, MD Janssen Research & Development, LLC · collab

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).

Timeline

Start: 2016-03-08
Primary completion: 2017-03-16
Completion: 2017-03-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Siltuximab	Monoclonal antibody	11 mg/kg	—

Indications